PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
October 19, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.Expected FDA clinical and commercial supply in...
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
October 13, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Achieving its second FDA orphan drug designation with ketamine.Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.Seeking to enter Phase 2...
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
October 06, 2021 09:03 ET
|
PharmaTher Holdings Ltd.
TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it...
PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
September 29, 2021 11:20 ET
|
PharmaTher Holdings Ltd.
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that...
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
September 28, 2021 17:41 ET
|
PharmaTher Holdings Ltd.
TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors
September 24, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE:...
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
September 21, 2021 09:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
September 13, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
10 clinical sites selected to participate in the FDA Phase 2 clinical study evaluating ketamine for the treatment of Parkinson’s DiseaseInitiated investigational new drug (IND) application to proceed...
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:51 ET
|
PharmaTher Holdings Ltd.
To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics TORONTO, Sept. ...
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
September 07, 2021 17:37 ET
|
PharmaTher Holdings Ltd.
TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released...